Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a developmental-stage biotech like Silo Pharma means wading through pages of clinical trial costs, licensing terms, and patent language. Whether you’re searching for “Silo Pharma insider trading Form 4 transactions” or trying to locate the exact burn-rate hidden in a 300-page annual report, the company’s filings can feel impenetrable.
Stock Titan’s AI reads every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR and translates them into plain English. Need a quick take on the latest “Silo Pharma quarterly earnings report 10-Q filing”? Our AI-powered summaries highlight R&D spend, cash runway, and key milestones in seconds. Wondering about “Silo Pharma executive stock transactions Form 4” before the next financing round? Real-time alerts surface each trade, complete with context. From “Silo Pharma proxy statement executive compensation” tables to “Silo Pharma 8-K material events explained”, complex biotech disclosures are now searchable, sortable, and understandable.
Dig deeper into what matters for a psychedelic-focused pipeline: see how university collaboration payments flow quarter over quarter, compare intellectual-property additions across years, and spot any dilution risks flagged in S-3 registrations. Investors use these insights to monitor trial progression (SPC-15, SP-26), assess non-dilutive funding potential, and evaluate management alignment through “Silo Pharma Form 4 insider transactions real-time”. Understanding Silo Pharma SEC documents with AI isn’t a luxury—it’s how professionals make informed calls on this evolving CNS therapeutics story.
Local Bounti Corporation (LOCL) has filed a Form 144 disclosing a planned disposition of restricted stock under Rule 144 of the Securities Act.
Seller: KEBS Trust
Planned sale: 3,500 common shares
Broker: Morgan Stanley Smith Barney, New York
Approximate sale date: 10 July 2025 (on the NYSE)
Aggregate market value: $9,261.35
Shares outstanding: 10,914,704
This transaction equals roughly 0.03 % of the company’s outstanding stock, indicating minimal dilution risk.
The shares were originally received as a gift from an affiliate on 28 December 2022. KEBS Trust has already executed several open-market sales in the past three months:
- 09 Jul 2025 – 200 shares – $602.00
- 22 May 2025 – 1,179 shares – $2,458.33
- 21 May 2025 – 600 shares – $1,262.52
- 20 May 2025 – 800 shares – $1,736.72
- 19 May 2025 – 1,000 shares – $2,226.60
- 16 May 2025 – 1,421 shares – $3,326.13
Total prior 3-month sales: 5,200 shares for gross proceeds of about $11,612. The signatory affirms no undisclosed adverse information and acknowledges SEC anti-fraud provisions.
CH Robinson Worldwide (CHRW) – Form 4 insider filing
On 01 Jul 2025, director Mark A. Goodburn received 380 immediately-vested Phantom Stock/RSUs at a reference price of $95.95 per share under the company’s director compensation deferral program. After the grant, Goodburn now holds 2,280 common shares directly plus 12,038 RSUs that convert 1-for-1 into common stock upon his departure from the board. No shares were sold and no cash changed hands; the transaction simply converts a quarterly cash retainer into equity, modestly increasing the director’s alignment with shareholders. The filing does not disclose any broader operational or financial information and is routine in nature.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
What is the core focus of Silo Pharma Inc?
How does Silo Pharma generate its revenue?
What are the key therapeutic programs of Silo Pharma?
What is unique about Silo Pharma's approach to drug delivery?
Who are Silo Pharma's research partners?
How does Silo Pharma protect its intellectual property?
What are the potential benefits of SPC-15?
In what ways does Silo Pharma demonstrate expertise in the industry?
